Holen Sie sich die Stockscreener-App
1.12
0.00%
0.00
Vorhandelsmarkt:
1.14
0.02
+1.79%
Schlusskurs vom Vortag:
$1.12
Offen:
$1.13
24-Stunden-Volumen:
61,511
Relative Volume:
0.36
Marktkapitalisierung:
$18.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.31M
KGV:
-0.6976
EPS:
-1.6054
Netto-Cashflow:
$-15.08M
1W Leistung:
-4.27%
1M Leistung:
+12.01%
6M Leistung:
-27.27%
1J Leistung:
+0.90%
1-Tages-Spanne:
$1.10
$1.17
1-Wochen-Bereich:
$1.045
$1.1799
52-Wochen-Spanne:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Firmenname
Allarity Therapeutics Inc
Sektor
Branche
Telefon
401-426-4664
Adresse
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.12 | 18.01M | 0 | -15.31M | -15.08M | -1.6054 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Aktie (ALLR) Neueste Nachrichten
Former Allarity Executive Winnows SEC’s FDA Approval Scheme Suit - Bloomberg Law News
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday - Defense World
Volume Summary: Will Allarity Therapeutics Inc stock recover after earningsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Pharma News: Can Allarity Therapeutics Inc expand its profit margins2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Allarity Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | C6D | US0167441049 - marketscreener.com
Aug Spikes: Whats the analyst consensus on Allarity Therapeutics IncGlobal Markets & AI Driven Stock Reports - baoquankhu1.vn
Inflation Data: Can Allarity Therapeutics Inc disrupt its industry2026 Technicals & Technical Entry and Exit Tips - baoquankhu1.vn
MACD Signal: Can Allarity Therapeutics Inc expand its profit marginsTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Big Picture: Is Allarity Therapeutics Inc backed by strong institutional buying2026 Momentum Check & Community Verified Watchlist Alerts - baoquankhu1.vn
Allarity Therapeutics Secures $20 Million Debt Financing to Advance Stenoparib Toward FDA Approval and Extend Cash Runway to 2028 - Minichart
Allarity closes $20M non-convertible debt to fund stenoparib Phase 2 and extend runway - TradingView
Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan
Allarity closes $20M financing for stenoparib advancement - Yahoo Finance
Allarity secures $20M debt financing to extend cash runway By Investing.com - Investing.com South Africa
Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding - marketscreener.com
Allarity Therapeutics, Inc. Closes $20 Million Non-Convertible Debt Financing - marketscreener.com
Allarity secures $20M debt financing to extend cash runway - Investing.com
Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Allarity Therapeutics closes $20 million financing to accelerate the advance of stenoparib toward FDA approval and commercialization - marketscreener.com
Allarity Therapeutics (ALLR) enters $20.93M secured note deal with covenants - Stock Titan
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib ... - Bluefield Daily Telegraph
Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization - TradingView
Allarity Therapeutics Closes $20 Million Financing to - GlobeNewswire
Aug Analyst Calls: What is Allarity Therapeutics Incs 5 year growth outlookJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Retail Trends: What are REV Group Incs earnings expectationsJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
ALLR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
First patients dosed in VA-funded stenoparib trial for lung cancer - Investing.com Australia
Allarity Therapeutics Doses First Patients in Phase 2 Lung Cancer Trial - marketscreener.com
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - The Manila Times
Allarity Therapeutics Initiates VA-Funded Phase 2 Trial of Stenoparib and Temozolomide for Relapsed Small Cell Lung Cancer - Quiver Quantitative
VA lung cancer trial tests new drug combo for patients with few options - Stock Titan
What is Allarity Therapeutics Inc. s 5 year growth outlook2025 Key Lessons & Detailed Earnings Play Strategies - mfd.ru
Why Allarity Therapeutics Inc. stock remains on buy listsWeekly Profit Report & Real-Time Volume Analysis - mfd.ru
Resistance Check: Is Allarity Therapeutics Inc stock good for income investorsJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Biotechnology company Allarity Therapeutics Inc recently filed documents with the U.S. Securities and Exchange Commission, disclosing that its selling shareholders plan to resell 255,103 shares of the company’s common stock. - Bitget
Value Recap: What is the next catalyst for Allarity Therapeutics IncTrade Risk Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
What is the target price for Portman Ridge Finance Corporation stockInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Allarity Therapeutics Inc. stock recover after earningsJuly 2025 Snapshot & Risk Controlled Stock Alerts - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Aug Setups: Will Wrap Technologies Inc face regulatory challengesJuly 2025 Weekly Recap & Entry Point Confirmation Signals - baoquankhu1.vn
Allarity Therapeutics Opens Enrollment for Phase 2 Trial in Lung Cancer - TradingView
Allarity begins phase 2 trial of stenoparib combination for lung cancer - Investing.com Nigeria
Allarity Therapeutics and US Veterans Administration open enrollment for mid-stage trial of stenoparib with temozolomide in relapsed small cell lung cancer - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - ChartMill
Finanzdaten der Allarity Therapeutics Inc-Aktie (ALLR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):